Clinical Trial Detail

NCT ID NCT03872180
Title Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Emory University
Indications

mantle cell lymphoma

Therapies

Bendamustine + Obinutuzumab + Venetoclax

Age Groups: adult senior

No variant requirements are available.